Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

Francesco Zaja; Marta Lisa Battista; Maria Teresa Pirrotta; Salvatore Palmieri; Michela Montagna; Nicola Vianelli; Luciana Marin; Margherita Cavallin; Monica Bocchia; Marzia Defina; Micaela Ippoliti; Felicetto Ferrara; Francesca Patriarca; Maria Antonietta Avanzini; Mario Regazzi; Michele Baccarani; Miriam Isola; Franca Soldano; Renato Fanin

doi:10.3324/haematol.12206

Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

Francesco Zaja, Marta Lisa Battista, Maria Teresa Pirrotta, Salvatore Palmieri, Michela Montagna, Nicola Vianelli, Luciana Marin, Margherita Cavallin, Monica Bocchia, Marzia Defina, Micaela Ippoliti, Felicetto Ferrara, Francesca Patriarca, Maria Antonietta Avanzini, Mario Regazzi, Michele Baccarani, Miriam Isola, Franca Soldano, Renato Fanin

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

Rituximab 375 mg/m² weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50×10 ⁹/L) and complete responses (platelet count > 100×10 ⁹/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.

Original language	English
Pages (from-to)	930-933
Number of pages	4
Journal	Haematologica
Volume	93
Issue number	6
DOIs	https://doi.org/10.3324/haematol.12206
Publication status	Published - Jun 2008

Keywords

B-cell depletion
Immune thrombocytopenia
Lower dose rituximab

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.12206

Fingerprint Dive into the research topics of 'Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura'. Together they form a unique fingerprint.

Cite this

Zaja, F., Battista, M. L., Pirrotta, M. T., Palmieri, S., Montagna, M., Vianelli, N., Marin, L., Cavallin, M., Bocchia, M., Defina, M., Ippoliti, M., Ferrara, F., Patriarca, F., Avanzini, M. A., Regazzi, M., Baccarani, M., Isola, M., Soldano, F., & Fanin, R. (2008). Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica, 93(6), 930-933. https://doi.org/10.3324/haematol.12206

Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. / Zaja, Francesco; Battista, Marta Lisa; Pirrotta, Maria Teresa; Palmieri, Salvatore; Montagna, Michela; Vianelli, Nicola; Marin, Luciana; Cavallin, Margherita; Bocchia, Monica; Defina, Marzia; Ippoliti, Micaela; Ferrara, Felicetto; Patriarca, Francesca; Avanzini, Maria Antonietta; Regazzi, Mario; Baccarani, Michele; Isola, Miriam; Soldano, Franca; Fanin, Renato.

In: Haematologica, Vol. 93, No. 6, 06.2008, p. 930-933.

Research output: Contribution to journal › Article › peer-review

Zaja, F, Battista, ML, Pirrotta, MT, Palmieri, S, Montagna, M, Vianelli, N, Marin, L, Cavallin, M, Bocchia, M, Defina, M, Ippoliti, M, Ferrara, F, Patriarca, F, Avanzini, MA, Regazzi, M, Baccarani, M, Isola, M, Soldano, F & Fanin, R 2008, 'Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura', Haematologica, vol. 93, no. 6, pp. 930-933. https://doi.org/10.3324/haematol.12206

Zaja, Francesco ; Battista, Marta Lisa ; Pirrotta, Maria Teresa ; Palmieri, Salvatore ; Montagna, Michela ; Vianelli, Nicola ; Marin, Luciana ; Cavallin, Margherita ; Bocchia, Monica ; Defina, Marzia ; Ippoliti, Micaela ; Ferrara, Felicetto ; Patriarca, Francesca ; Avanzini, Maria Antonietta ; Regazzi, Mario ; Baccarani, Michele ; Isola, Miriam ; Soldano, Franca ; Fanin, Renato. / Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. In: Haematologica. 2008 ; Vol. 93, No. 6. pp. 930-933.

@article{9ffd6b74ea514bda8f686eeec6d128fc,

title = "Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura",

abstract = "Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50×10 9/L) and complete responses (platelet count > 100×10 9/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.",

keywords = "B-cell depletion, Immune thrombocytopenia, Lower dose rituximab",

author = "Francesco Zaja and Battista, {Marta Lisa} and Pirrotta, {Maria Teresa} and Salvatore Palmieri and Michela Montagna and Nicola Vianelli and Luciana Marin and Margherita Cavallin and Monica Bocchia and Marzia Defina and Micaela Ippoliti and Felicetto Ferrara and Francesca Patriarca and Avanzini, {Maria Antonietta} and Mario Regazzi and Michele Baccarani and Miriam Isola and Franca Soldano and Renato Fanin",

year = "2008",

month = jun,

doi = "10.3324/haematol.12206",

language = "English",

volume = "93",

pages = "930--933",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

number = "6",

}

TY - JOUR

T1 - Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

AU - Zaja, Francesco

AU - Battista, Marta Lisa

AU - Pirrotta, Maria Teresa

AU - Palmieri, Salvatore

AU - Montagna, Michela

AU - Vianelli, Nicola

AU - Marin, Luciana

AU - Cavallin, Margherita

AU - Bocchia, Monica

AU - Defina, Marzia

AU - Ippoliti, Micaela

AU - Ferrara, Felicetto

AU - Patriarca, Francesca

AU - Avanzini, Maria Antonietta

AU - Regazzi, Mario

AU - Baccarani, Michele

AU - Isola, Miriam

AU - Soldano, Franca

AU - Fanin, Renato

PY - 2008/6

Y1 - 2008/6

N2 - Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50×10 9/L) and complete responses (platelet count > 100×10 9/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.

AB - Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50×10 9/L) and complete responses (platelet count > 100×10 9/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.

KW - B-cell depletion

KW - Immune thrombocytopenia

KW - Lower dose rituximab

UR - http://www.scopus.com/inward/record.url?scp=44949126978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949126978&partnerID=8YFLogxK

U2 - 10.3324/haematol.12206

DO - 10.3324/haematol.12206

M3 - Article

C2 - 18403395

AN - SCOPUS:44949126978

VL - 93

SP - 930

EP - 933

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -